Table 1.

Systematic literature review eligibility criteria

	Eligibility criteria
Populations	•Patients treated with intravitreal injections using prefilled syringes containing single-pathway anti-VEGF treatments •Clinicians preparing and administering the above
Interventions	Anti-VEGF prefilled syringes approved for treating retinal diseases •Ranibizumab •Aflibercept •Brolucizumab
Comparators	Anti-VEGF vials approved for treating retinal diseases •Ranibizumab •Aflibercept •Brolucizumab
Outcomes	Procedural efficiency •Preparation and/or injection time •Preparation and/or injection costs •Preparation and/or injection steps •Precision of intravitreal dosing •Convenience/procedural simplicity •Handling errors or contamination •Wastage (drug or other components) Health care resource use •Supplies used per injection (e.g., needles, syringes) •Effects on staff/clinic management/health system •Cost-effectiveness Patient and clinician experience •Patient preference or satisfaction •Clinician preference or satisfaction •Patient health-related quality of life Safety •Transient vision loss •Increased intraocular pressure •Intraocular inflammation/endophthalmitis •Vitreous floaters •Intraocular air bubbles/silicone oil droplets/subvisible particles •Treatment discontinuation/withdrawal because of adverse events •Preventable adverse events (associated with handling and administration)
Studies/publication types	•Any literature reporting on the outcomes of interest in patients treated with intravitreal injections using prefilled syringes containing ranibizumab, aflibercept, or brolucizumab •Any literature reporting on health care providers preparing and administering such injections •Literature reporting results involving off-label compounding of prefilled syringe or splitting practices will be excluded
Publication dates	•January 1, 2015 to February 8, 2024

VEGF vascular endothelial growth factor